CD4:CD8 Ratio and CD8 Cell Count and Their Prognostic Relevance for Coronary Heart Disease Events and Stroke in Antiretroviral Treated Individuals: The Swiss HIV Cohort Study.

Détails

Ressource 1Télécharger: 36150371_BIB_F9E3B19F99FD.pdf (199.86 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_F9E3B19F99FD
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
CD4:CD8 Ratio and CD8 Cell Count and Their Prognostic Relevance for Coronary Heart Disease Events and Stroke in Antiretroviral Treated Individuals: The Swiss HIV Cohort Study.
Périodique
Journal of acquired immune deficiency syndromes
Auteur⸱e⸱s
Chammartin F., Darling K., Abela I.A., Battegay M., Furrer H., Calmy A., Bernasconi E., Schmid P., Hoffmann M., Bucher H.C.
Collaborateur⸱rice⸱s
and the Swiss HIV Cohort Study
ISSN
1944-7884 (Electronic)
ISSN-L
1525-4135
Statut éditorial
Publié
Date de publication
15/12/2022
Peer-reviewed
Oui
Volume
91
Numéro
5
Pages
508
Langue
anglais
Notes
Publication types: Observational Study ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
HIV infection leads to a persistent expansion of terminally CD8 T cells and CD8 T suppressor cells, a marker of chronic immune activation leading to a low CD4:CD8 ratio that may persist in the presence of potent antiretroviral therapy and regained CD4 helper cells. It remains unclear whether a low CD4:CD8 ratio is associated with cardiovascular diseases.
We conducted an observational cohort study to investigate the association of immune depression and activation as characterized by the proxy of the CD4:CD8 ratio on the hazard of coronary heart disease (CHD) and stroke among treated individuals living with HIV, while accounting for viral load and known risk factors for cardiovascular diseases and exposure to abacavir or protease inhibitors. We used Cox proportional hazard models with time-dependent cumulative and lagged exposures to account for time-evolving risk factors and avoid reverse causality.
CD4, CD8, and CD4:CD8 immunological markers were not associated with an increased hazard for CHD. CD8 cell count lagged at 12 months above 1000 cells per μL increased the hazard of stroke, after adjusting for sociodemographics, cardiovascular risk factors, and exposure to specific types of antiretroviral drugs.
This analysis of treated HIV-positive individuals within a large cohort with long-term follow-up does not provide evidence for a prognostic role of immune dysregulation regarding CHD. However, increased CD8 cell count may be a moderate risk factor for stroke. Early detection and treatment of HIV-positive individuals are crucial for an optimal immune restoration and a limited CD8 cells expansion.
Mots-clé
Humans, CD4-CD8 Ratio, HIV Infections/complications, HIV Infections/drug therapy, Cohort Studies, Prognosis, Cardiovascular Diseases/drug therapy, Switzerland, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Anti-Retroviral Agents/adverse effects, Viral Load, Biomarkers, Coronary Disease/epidemiology, Stroke/epidemiology, CD4 Lymphocyte Count, Anti-HIV Agents/adverse effects
Pubmed
Web of science
Open Access
Oui
Création de la notice
04/10/2022 11:08
Dernière modification de la notice
25/01/2024 8:47
Données d'usage